Emerging Treatment Options for Patients With Kidney Cancer
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
- New emerging treatment options are all trial-based
- There are newer antiangiogenic agents that are just as efficacious but generate less toxicity
- Researchers and oncologists are excited about immunotherapy for the treatment of kidney cancer
- New immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
May 6th 2024The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for February 28, 2025.
Read More
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
